Products Raltegravir
Raltegravir Approved Completed 🔥 Hot HIV Prevention, HIV Infections
Jul 1, 2010 → Jul 1, 2012
About Raltegravir Raltegravir is a approved stage product being developed by Merck for HIV Prevention. The current trial status is completed. This product is registered under clinical trial identifier NCT01087840. Target conditions include HIV Prevention, HIV Infections.
Clinical Trials (20) NCT ID Phase Status Start Completion Indication NCT00377065 Pre-clinical Completed — — HIV Infections NCT03732625 Approved UNKNOWN May 1, 2019 Jan 1, 2021 HIV Infections NCT03667547 Approved Completed Sep 27, 2018 Oct 23, 2018 Human Immunodeficiency Virus (HIV) Infection NCT03374358 Approved Completed Jan 10, 2018 Nov 30, 2019 HIV Seropositivity NCT02097108 Phase 2 Completed May 1, 2014 Dec 1, 2015 HIV Infections NCT01978743 Pre-clinical Completed Jan 1, 2014 Jan 1, 2017 HIV NCT01767701 Phase 2 Completed Apr 1, 2013 Sep 1, 2014 Relapsing Remitting Multiple Sclerosis NCT01453933 Approved UNKNOWN Jan 1, 2012 Dec 1, 2014 HIV Infection NCT01620736 Phase 2 Withdrawn Jan 1, 2012 Dec 1, 2014 Human T-cell Leukemia Virus Type 1 Infection NCT01453192 Phase 3 Completed Dec 1, 2011 Nov 1, 2015 HIV-1 Infection NCT01448486 Approved Terminated Oct 1, 2011 Oct 1, 2013 Human Immunodeficiency Virus (HIV) NCT01327482 Pre-clinical Completed Oct 1, 2011 — HIV NCT01325051 Phase 1 Completed Apr 1, 2011 Nov 1, 2011 Healthy Volunteer NCT01042652 Pre-clinical UNKNOWN Feb 1, 2011 Jun 1, 2012 HIV NCT01164605 Pre-clinical UNKNOWN Oct 1, 2010 Jun 1, 2013 HIV Infection NCT01087840 Approved Completed Jul 1, 2010 Jul 1, 2012 HIV Prevention NCT01027182 Phase 1 Completed Dec 1, 2009 Mar 1, 2010 Human Immunodeficiency Virus NCT00939874 Approved Completed Oct 1, 2009 Apr 1, 2014 HIV NCT00807443 Phase 2 Completed Sep 1, 2009 Dec 1, 2011 HIV-1 NCT00887653 Phase 3 Completed May 1, 2009 Apr 1, 2014 HIV
Product Company Stage Hype Score edoxaban + enoxaparin sodium Daiichi Sankyo Phase 3 Mifepristone Eli Lilly Phase 2 EXANTA AstraZeneca Phase 2 Risk of low dose aspirin discontinuation AstraZeneca Pre-clinical DAPA/MET XR + DAPA + MET XR AstraZeneca Phase 3 Esomeprazole + Placebo AstraZeneca Phase 3 PCV15 Merck Pre-clinical RotaTeq (V260) + IPV Merck Phase 3 V501 Merck Phase 3 Zostavax Merck Phase 3 V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920 Merck Phase 3 Letermovir + Placebo Merck Phase 3 Meningococcal C conjugate vaccine Novartis Approved Enteric-coated mycophenolate sodium Novartis Phase 3 Meningococcal C conjugate vaccine Novartis Approved rMenB+OMV NZ Novartis Phase 3 Enteric-Coated Mycophenolate Sodium Novartis Phase 3 Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Placebo in 1.5ml Novartis Phase 3 Meningococcal C Conjugate Vaccine Novartis Phase 3 MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation) + MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation) + MenACWY PS (MenACWY-CRM, polysaccharide vaccine) + HBV (Hepatitis B vaccine) + Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197) + MMR (Measles, Mumps and Rubella vaccine) + DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine) + Menjugate (Men C conjugated vaccine) Novartis Phase 2
Other Products from Merck